Market Place
Sourcing Support
Incyte Claims Double Phase 3 Wins in Vitiligo, Plans NDA Filing
29 Apr 2026 //
ENDPOINTS
Incyte Exceeds Q1 Estimates With Strong Cancer Drug Demand
28 Apr 2026 //
REUTERS
Incyte Gets CHMP Nod For Zynyz In Anal Canal Cancer
30 Jan 2026 //
BUSINESSWIRE
Incyte to seek FDA approval for Monjuvi in front-line DLBCL
05 Jan 2026 //
BUSINESSWIRE
Japan Approves Incyte`s Minjuvi for R/R Follicular Lymphoma
22 Dec 2025 //
BUSINESSWIRE
Incyte Japan Approves Zynyz For First-Line Advanced Anal Cancer
22 Dec 2025 //
BUSINESSWIRE
EU Approves Minjuvi for Relapsed/Refractory Follicular Lymphoma
17 Dec 2025 //
BUSINESSWIRE
Incyte Presents INCA033989 Data for ET at ASH 2025
08 Dec 2025 //
BUSINESSWIRE
Incyte` INCA033989, Receives FDA Breakthrough Therapy Designation
07 Dec 2025 //
BUSINESSWIRE
Incyte Presents INCA033989 Data in Myelofibrosis at ASH 2025
07 Dec 2025 //
BUSINESSWIRE
Incyte Gets CHMP Nod For Minjuvi In Relapsed Follicular Lymphoma
17 Nov 2025 //
BUSINESSWIRE
Prelude Loses CMO, Pauses SMARCA2 Degraders, Scores Incyte Cash
04 Nov 2025 //
FIERCE BIOTECH
Incyte To Present Over 50 Abstracts at 2025 ASH Meeting
03 Nov 2025 //
BUSINESSWIRE
Incyte Reveals Phase 1 Data On TGF?r2×Pd-1 Bispecific Antibody
19 Oct 2025 //
BUSINESSWIRE
Incyte To Present Tgf?r2×Pd-1 Antibody And KRAS G12D Inhibitor
14 Oct 2025 //
BUSINESSWIRE
Incyte to Present Bispecific and KRAS Data at ESMO 2025
24 Jul 2025 //
BUSINESSWIRE
FDA Reviewing Opzelura Cream for Kids With Dermatitis
20 Jun 2025 //
BUSINESSWIRE
Incyte Announces FDA Approval of Monjuvi for Lymphoma
19 Jun 2025 //
BUSINESSWIRE
Specialised Therapeutics Expands Incyte Deal With 2 Therapies
12 Jun 2025 //
PR NEWSWIRE
Incyte Announces Multiple Presentation, Late-Breaking Data at EHA
03 Jun 2025 //
BUSINESSWIRE
Incyte Secures Anal Cancer Nods Years After FDA Rejection
17 May 2025 //
FIERCE PHARMA
Incyte pens $885M AI pact to use Genesis` GEMS to develop drugs
21 Feb 2025 //
FIERCE BIOTECH
Incyte & Genesis Partner For AI-Driven Drug Discovery Research
20 Feb 2025 //
BUSINESSWIRE
Incyte & Syndax Gain FDA Approval For New Cancer Treatment Sizes
15 Jan 2025 //
PR NEWSWIRE
Incyte Monjuvi Data Shows Improved Survival In Follicular Lymphoma
10 Dec 2024 //
BUSINESSWIRE
Incyte`s Retifanlimab Plus Chemotherapy Positive in Lung Cancer Trial
07 Dec 2024 //
BUSINESSWIRE
Incyte`s Monjuvi proves its worth in follicular lymphoma
26 Nov 2024 //
FIERCE PHARMA
Incyte’s $750M buyout rocked by pause on key trial, asset cull
18 Nov 2024 //
FIERCE BIOTECH
Incyte wins injunction to block Sun`s Leqselvi launch
05 Nov 2024 //
FIERCE PHARMA
Incyte & Syndax Publish AGAVE-201 Trial Data on Axatilimab in GVHD
18 Sep 2024 //
PR NEWSWIRE
Incyte To Present Phase 3 Results For Retifanlimab At ESMO 2024
22 Aug 2024 //
BUSINESSWIRE
Incyte Seeks Monjuvi Label Expansion After Phase 3 Lymphoma Win
19 Aug 2024 //
FIERCE PHARMA
Silence breaks phase 1 data on blood disorder prospect
27 Jun 2024 //
FIERCE BIOTECH
Incyte Announces U.S. FDA Grants Priority Review for Axatilimab
27 Feb 2024 //
BUSINESSWIRE
Incyte Gains Development and Commercialization Rights to Tafasitamab (Monjuvi®)
05 Feb 2024 //
BUSINESSWIRE
Incyte Presents at The 43rd William Blair Growth Stock Conference, Jun-06-2023
02 Jun 2023 //
MARKETSCREENER
BlackRock Inc. Increases Position in Incyte Corporation (INCY)
25 Jan 2023 //
NASDAQ
